JP2014524936A5 - - Google Patents

Download PDF

Info

Publication number
JP2014524936A5
JP2014524936A5 JP2014523106A JP2014523106A JP2014524936A5 JP 2014524936 A5 JP2014524936 A5 JP 2014524936A5 JP 2014523106 A JP2014523106 A JP 2014523106A JP 2014523106 A JP2014523106 A JP 2014523106A JP 2014524936 A5 JP2014524936 A5 JP 2014524936A5
Authority
JP
Japan
Prior art keywords
group
formula
pharmaceutically acceptable
prodrug
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014523106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524936A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/048820 external-priority patent/WO2013016727A1/en
Publication of JP2014524936A publication Critical patent/JP2014524936A/ja
Publication of JP2014524936A5 publication Critical patent/JP2014524936A5/ja
Pending legal-status Critical Current

Links

JP2014523106A 2011-07-28 2012-07-30 システインプロドラッグ Pending JP2014524936A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161512751P 2011-07-28 2011-07-28
US61/512,751 2011-07-28
PCT/US2012/048820 WO2013016727A1 (en) 2011-07-28 2012-07-30 Cysteine prodrugs

Publications (2)

Publication Number Publication Date
JP2014524936A JP2014524936A (ja) 2014-09-25
JP2014524936A5 true JP2014524936A5 (enExample) 2015-09-03

Family

ID=47601579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014523106A Pending JP2014524936A (ja) 2011-07-28 2012-07-30 システインプロドラッグ

Country Status (5)

Country Link
US (2) US9457014B2 (enExample)
EP (1) EP2736890A4 (enExample)
JP (1) JP2014524936A (enExample)
CA (1) CA2842106A1 (enExample)
WO (1) WO2013016727A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2842106A1 (en) * 2011-07-28 2013-01-31 Promentis Pharmaceuticals, Inc. Cysteine prodrugs
WO2013188877A1 (en) * 2012-06-15 2013-12-19 Promentis Pharmaceuticals, Inc. The use of compounds elevating glutathione levels for the treatment of parkinson's disease
US20150045312A1 (en) * 2013-08-12 2015-02-12 Promentis Pharmaceuticals, Inc. Use of Compounds Elevating Glutathione Levels for the Treatment of Autism, Autistic Spectrum Disorders and Fragile X Syndrome
LT3066089T (lt) * 2013-11-08 2020-02-25 Promentis Pharmaceuticals, Inc. Pakeistieji n-acetil-l-cisteino dariniai ir giminingi junginiai
WO2016044314A1 (en) * 2014-09-15 2016-03-24 Sound Pharmaceuticals Incorporated Methods and compositions for treating psychotic disorders
KR102474830B1 (ko) 2016-05-18 2022-12-06 사운드 파마슈티칼스 인코퍼레이티드 중이염의 치료
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
KR102506333B1 (ko) 2016-12-20 2023-03-06 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피흡수 치료 시스템
EP3644973B1 (en) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
CN118593482A (zh) 2017-12-05 2024-09-06 赛诺维信制药公司 非外消旋混合物及其用途
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
US20220098177A1 (en) * 2018-12-31 2022-03-31 Zymergen Inc. Polymer compositions comprising compounds derived from biology
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CN113024473B (zh) * 2021-04-13 2022-08-23 陕西慧康生物科技有限责任公司 一种含有半胱氨酸的环二肽的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT995110B (it) * 1973-08-01 1975-11-10 Snam Progetti Procedimento per la produzione di composti eterociclici e prodotti ottenuti
JPS6016989A (ja) 1983-07-06 1985-01-28 Shionogi & Co Ltd オキソ飽和異項環カルボンアミドセフエム化合物
US5298516A (en) * 1991-03-27 1994-03-29 Sankyo Company, Limited Thiazolidone compounds and method of using the same as a vasodilator
AU682894B2 (en) * 1993-10-28 1997-10-23 Institut National De La Recherche Agronomique Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
AU6676100A (en) * 1999-08-17 2001-03-13 University Of Saskatchewan Technologies Inc. Improved treatment for acute physical insult to the central nervous system
US7829709B1 (en) * 2007-08-10 2010-11-09 Marquette University Cysteine prodrugs to treat schizophrenia and drug addiction
WO2009100431A1 (en) * 2008-02-07 2009-08-13 Marquette University Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings
CA2842106A1 (en) * 2011-07-28 2013-01-31 Promentis Pharmaceuticals, Inc. Cysteine prodrugs

Similar Documents

Publication Publication Date Title
JP2014524936A5 (enExample)
JP2016539144A5 (enExample)
JP6804790B1 (ja) N4−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
JP2015505296A5 (enExample)
JP2017519781A5 (enExample)
JP2017514830A5 (enExample)
JP2016510323A5 (enExample)
HRP20201043T1 (hr) Spojevi 4-amino-imidazokinolina
JP2019526596A5 (enExample)
JP2009263394A5 (enExample)
JP2013510120A5 (enExample)
RU2015128794A (ru) Композиция перорально распадающейся таблетки, обеспечивающая повышенную биодоступность
US20210002295A1 (en) Small molecule degraders that recruit dcaf15
JP2015520140A5 (enExample)
HRP20150770T1 (hr) Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin
HRP20161577T1 (hr) Inhibitori replikacije virusa gripe
JP2013514980A5 (enExample)
JP2017525668A5 (enExample)
JP2017505293A5 (enExample)
CN107759585A (zh) 一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用
JP2014521744A5 (enExample)
ME02576B (me) Derivati tetrahidropirolotiazina kao inhibitori bace
JP2002030084A5 (enExample)
JP2019526546A5 (enExample)
JP2005527542A5 (enExample)